TD Asset Management Inc Sells 16,200 Shares of CRISPR Therapeutics AG $CRSP

TD Asset Management Inc trimmed its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 158,416 shares of the company’s stock after selling 16,200 shares during the period. TD Asset Management Inc owned 0.17% of CRISPR Therapeutics worth $8,307,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Capital International Investors raised its stake in CRISPR Therapeutics by 1.0% in the third quarter. Capital International Investors now owns 5,649,258 shares of the company’s stock valued at $366,128,000 after buying an additional 55,511 shares during the last quarter. State Street Corp increased its holdings in shares of CRISPR Therapeutics by 35.6% during the second quarter. State Street Corp now owns 3,270,596 shares of the company’s stock valued at $159,082,000 after acquiring an additional 859,334 shares in the last quarter. Orbis Allan Gray Ltd increased its holdings in shares of CRISPR Therapeutics by 76.9% during the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock valued at $134,467,000 after acquiring an additional 1,201,600 shares in the last quarter. UBS Group AG raised its position in shares of CRISPR Therapeutics by 7.7% in the 4th quarter. UBS Group AG now owns 2,524,144 shares of the company’s stock valued at $132,366,000 after purchasing an additional 180,580 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in CRISPR Therapeutics by 2.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,364,645 shares of the company’s stock worth $153,253,000 after purchasing an additional 66,556 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CRSP has been the subject of several recent research reports. Chardan Capital raised their target price on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a report on Saturday, February 14th. Truist Financial upgraded CRISPR Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Evercore reiterated an “outperform” rating and set a $76.00 price target on shares of CRISPR Therapeutics in a research report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Monday, April 20th. Finally, Morgan Stanley reaffirmed an “underweight” rating and set a $33.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $65.47.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ:CRSP opened at $51.48 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 17.97 and a quick ratio of 17.96. CRISPR Therapeutics AG has a 1 year low of $39.81 and a 1 year high of $78.48. The firm has a market capitalization of $4.97 billion, a PE ratio of -8.28 and a beta of 1.74. The business’s 50 day moving average price is $52.23 and its 200-day moving average price is $53.11.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The firm had revenue of $1.46 million during the quarter. As a group, equities research analysts expect that CRISPR Therapeutics AG will post -4.92 earnings per share for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the transaction, the insider directly owned 19,357 shares of the company’s stock, valued at $1,076,636.34. This trade represents a 16.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel James R. Kasinger sold 3,450 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $48.26, for a total value of $166,497.00. Following the transaction, the general counsel owned 91,240 shares in the company, valued at approximately $4,403,242.40. This represents a 3.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 33,937 shares of company stock valued at $1,646,126. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.